Cutler Group LLC CA Buys 600 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Cutler Group LLC CA grew its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDXFree Report) by 600.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 700 shares of the company’s stock after buying an additional 600 shares during the quarter. Cutler Group LLC CA’s holdings in TransMedics Group were worth $38,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its holdings in TransMedics Group by 2.4% in the 2nd quarter. BlackRock Inc. now owns 2,309,393 shares of the company’s stock valued at $193,943,000 after buying an additional 54,776 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of TransMedics Group by 14.5% during the third quarter. Vanguard Group Inc. now owns 1,644,691 shares of the company’s stock valued at $68,650,000 after acquiring an additional 208,377 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of TransMedics Group by 36.6% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,294,430 shares of the company’s stock worth $108,706,000 after purchasing an additional 346,727 shares during the period. Driehaus Capital Management LLC grew its stake in shares of TransMedics Group by 8.4% in the second quarter. Driehaus Capital Management LLC now owns 1,162,214 shares of the company’s stock worth $97,603,000 after purchasing an additional 90,023 shares during the last quarter. Finally, Summit Partners Public Asset Management LLC grew its stake in shares of TransMedics Group by 71.9% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock worth $59,083,000 after purchasing an additional 400,255 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on TransMedics Group from $67.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 7th. Morgan Stanley lifted their price objective on TransMedics Group from $54.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.33.

View Our Latest Report on TMDX

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $89.20 on Friday. The stock’s 50-day moving average is $80.48 and its 200 day moving average is $67.57. The company has a debt-to-equity ratio of 4.00, a quick ratio of 10.13 and a current ratio of 10.93. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $99.63.

TransMedics Group (NASDAQ:TMDXGet Free Report) last posted its quarterly earnings results on Monday, November 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.06. The firm had revenue of $66.43 million for the quarter, compared to analysts’ expectations of $48.05 million. TransMedics Group had a negative return on equity of 8.77% and a negative net margin of 18.65%. As a group, equities analysts anticipate that TransMedics Group, Inc. will post -0.33 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 2,330 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the completion of the sale, the insider now directly owns 14,375 shares in the company, valued at $1,295,043.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 10,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total value of $804,100.00. Following the transaction, the insider now owns 14,375 shares in the company, valued at $1,155,893.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 2,330 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the completion of the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. Insiders have sold 63,609 shares of company stock worth $5,080,994 in the last quarter. Company insiders own 6.70% of the company’s stock.

TransMedics Group Company Profile

(Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Read More

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDXFree Report).

Institutional Ownership by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.